The systematic review using PRISMA guidelines yielded 1,490 initial articles, of which 937 were screened and 10 met the inclusion criteria
[7] reported that 17.6% of the patients had a WR higher than 10% after the primary MBS (SG and RYGB) in a mean follow-up duration of 62 months
Abstract Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by excess cardiovascular risk
GLP-1 use surges Big picture view: The findings come as policymakers and insurers grapple with the growing demand for GLP-1 drugs
They found that for FDA approved GLP-1s for weight loss, liraglutide (Saxenda) and semaglutide (Wegovy), the percent of side effects reported was as follows: Nausea: 42.2% Diarrhea: 21.9% Vomiting: also 21.9% Constipation: 8.4% They report that although the incidence of side effects were similar among medications, semaglutide had the greatest risk of nausea, diarrhea, and vomiting, whereas liraglutide had the greatest risk of upper abdominal pain
What to expect when switching First, youll need a new prescription for an oral GLP-1
